Proxima, a portable hematology analyzer from Algocyte, aims to perform finger-prick blood-count tests and deliver results to clinicians in about 20 minutes, potentially reducing trips to clinics for patients needing frequent monitoring.

The device carries UKCA regulatory marking and is undergoing further testing, regulatory steps, and commercial deployment, with broader clinical validation trials planned.

Algocyte blends AI, bioengineering, computational biology, and clinical medicine, showcasing academia translating research into scalable healthcare technology.

A key next step is published clinical evidence comparing Proxima’s performance to established analyzers, including test failure or repeat rates and real-world usability when samples aren’t handled by lab staff.

The PROXIMA Mobile Health Station was launched on a summer date at the Royal Society of Medicine in London to mark the UKCA milestone and discuss future development, validation, and applications across healthcare.

Algocyte plans supervised use by healthcare workers first, with home monitoring as a longer-term goal, and calls for public performance data comparing Proxima with reference analyzers across all claimed markers.

The device uses a smartphone app and dual sensing systems; AI translates sample signals into measurements for markers like red/white blood cells, platelets, and hemoglobin, with results delivered to a clinician dashboard rather than patients.

Unlike one-off tests, Proxima tracks small health changes over time, potentially enabling earlier detection and monitoring for patients needing regular tests, such as those on chemotherapy or medications requiring close blood monitoring.

King’s College London spinout Algocyte developed a portable device enabling remote health monitoring via Bluetooth, using AI to build a longitudinal health profile from at-home blood samples.

The technology could free NHS resources by reducing dependence on hospital or GP visits for routine blood work, addressing millions of annual UK tests.

The article notes ongoing scrutiny of finger-prick testing and emphasizes that Proxima is a supervised hematology tool, not a complete replacement for clinical laboratories.

Patients provide small finger-prick samples, the device analyzes them on-site, and results are shared digitally with doctors and patients.